Which diagnostic tests should be performed to evaluate for diabetes and screen for its complications?

Diagnostic Tests for Diabetes

Use A1C ≥6.5%, fasting plasma glucose (FPG) ≥126 mg/dL, or 2-hour plasma glucose ≥200 mg/dL during a 75-gram oral glucose tolerance test (OGTT) to diagnose diabetes—all three tests are equally appropriate, though FPG is preferred for its superior specificity and practical advantages. 1

Primary Diagnostic Tests

The diagnosis of diabetes requires one of the following criteria 1:

• A1C ≥6.5% (48 mmol/mol) - Must be performed in an NGSP-certified laboratory
• FPG ≥126 mg/dL (7.0 mmol/L) - After at least 8-hour fast
• 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during 75-gram OGTT
• Random plasma glucose ≥200 mg/dL (11.1 mmol/L) with classic hyperglycemic symptoms (polyuria, polydipsia, unexplained weight loss)

Confirmation Requirements

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results 1. You can confirm diabetes by:

1. Repeating the same test on a different day (e.g., A1C 7.0% followed by repeat A1C 6.8% confirms diabetes)
2. Using two different tests above diagnostic thresholds from the same sample (e.g., A1C ≥6.5% AND FPG ≥126 mg/dL)
3. Using two different tests from separate samples

If a patient has classic symptoms of hyperglycemia with random glucose ≥200 mg/dL, no confirmation is needed 1.

Choosing Between Tests

Recent network meta-analysis demonstrates that FPG ≥126 mg/dL has the highest specificity (0.98) and positive likelihood ratio (21.94) compared to A1C and combined testing 2. However, each test has distinct advantages 3, 1:

FPG advantages:

• Highest specificity (98%)
• Inexpensive and widely available
• Well-standardized

FPG limitations:

• Requires 8-hour fast
• High day-to-day variability (12-15%)
• Poor preanalytic stability—samples must be centrifuged immediately or kept on ice

A1C advantages:

• No fasting required
• Reflects 2-3 month glucose exposure
• Excellent preanalytic stability
• Lowest within-person variability
• Unaffected by acute stress, illness, or recent food intake

A1C limitations:

• More expensive
• Cannot be used with hemoglobin variants, hemolytic anemia, recent blood loss/transfusion, pregnancy (2nd/3rd trimester), or conditions with altered RBC turnover 4, 1
• Lower sensitivity (42.8% at ≥6.5% cutpoint) 2

2-hour OGTT advantages:

• Identifies more people with diabetes than FPG or A1C
• Most interventions for prediabetes prevention were studied in populations identified by OGTT 1

2-hour OGTT limitations:

• Poorest reproducibility
• Requires 8-hour fast plus 2-hour wait
• Patient compliance issues

Screening for Prediabetes

Test for prediabetes using the same tests (A1C, FPG, or 2-hour OGTT) in adults who are overweight/obese (BMI ≥25 kg/m² or ≥23 kg/m² in Asian Americans) with additional risk factors 4:

• First-degree relative with diabetes
• High-risk race/ethnicity (African American, Latino, Native American, Asian American, Pacific Islander)
• History of cardiovascular disease
• Hypertension (≥140/90 mmHg or on therapy)
• HDL <35 mg/dL or triglycerides >250 mg/dL
• Women with polycystic ovary syndrome
• Physical inactivity
• Previous gestational diabetes
• A1C ≥5.7%, impaired glucose tolerance, or impaired fasting glucose on prior testing

For those without risk factors, begin screening at age 45 years 5, 4.

Prediabetes Diagnostic Thresholds 1:

• A1C: 5.7-6.4%
• FPG: 100-125 mg/dL (impaired fasting glucose)
• 2-hour OGTT: 140-199 mg/dL (impaired glucose tolerance)

Screening Intervals

• Normal results: Repeat testing at minimum 3-year intervals 5, 3
• Prediabetes: Test annually 4
• Women with prior gestational diabetes: Lifelong testing at least every 3 years 4

Critical Technical Considerations

To prevent misdiagnosis from glycolysis 3:

• Use tubes with granulated citrate buffer (rapidly effective glycolytic inhibitor)
• If unavailable, immediately place sample in ice-water slurry
• Centrifuge within 15-30 minutes to separate plasma
• Do NOT rely on sodium fluoride alone—it only inhibits enolase and allows continued glycolysis

For A1C testing: Use only NGSP-certified laboratory methods standardized to the DCCT assay. Point-of-care A1C devices should only be used if FDA-approved for diagnosis at CLIA-certified laboratories 1.

Screening for Complications

Once diabetes is diagnosed, screen for complications 6:

Nephropathy:

• Urine albumin-to-creatinine ratio (ACR)
  • Normal: <30 mg/g
  • Moderately increased (A2): 30-300 mg/g
  • Severely increased (A3): >300 mg/g

Retinopathy:

• Dilated eye examination at diagnosis for type 2 diabetes, within 5 years for type 1 diabetes

Neuropathy:

• Comprehensive foot examination including 10-g monofilament testing, vibration perception, ankle reflexes

Cardiovascular disease:

• Blood pressure measurement
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)

Common Pitfalls

Discordant results: If two different tests disagree (e.g., A1C ≥6.5% but FPG <126 mg/dL), repeat the test that exceeded the diagnostic threshold. The diagnosis is based on the confirmed abnormal test 5, 7.

A1C interference: Marked discrepancies between A1C and plasma glucose should prompt consideration of assay unreliability due to hemoglobin variants or conditions affecting RBC turnover 4, 1.

Preanalytic errors: The most common cause of falsely low glucose values is delayed sample processing—glucose decreases approximately 5-7% per hour at room temperature 3.